Reactions 1680, p333 - 2 Dec 2017
DRESS syndrome: case report
A 51-year-old man developed DRESS syndrome during
treatment with vemurafenib [route and dosage not stated].
The man with lentigo maligna melanoma of the ear was
referred for lung, brain, liver and subcutaneous metastases at
the age of 46 years. Five years later, he was initiated on
vemurafenib treatment due to the progression of lung
metastases. After 21 days of vemurafenib initiation, he
presented with maculopapular exanthema and facial oedema.
His laboratory tests showed eosinophilia with liver cytolysis
and renal insufficiency. Consequently, he was diagnosed with
DRESS syndrome, with a REGISCAR score of 6. As he was only
receiving treatment with vemurafenib; his DRESS syndrome
was considered to be caused by vemurafenib.
As a result, the man’s vemurafenib was discontinued. He
was initiated on corrective treatment with topical
corticosteroids and prednisone. Within two weeks of
vemurafenib discontinuation and start of corticosteroids, his
laboratory tests and clinical condition improved. He was then
started on nivolumab, followed by ipilimumab for the
treatment of metastatic lentigo maligna melanoma. However,
due to the progression of liver and a new bone metastasis,
dabrafenib was started. He achieved partial remission during
treatment with dabrafenib, without any recurrence of DRESS
Author comment: "We report the case of a patient with
metastatic malignant melanoma in whom DRESS developed
likely from vemurafenib."
Pinard C, et al. Successful use of dabrafenib after the occurrence of drug rash with
eosinophilia and systemic symptoms (DRESS) induced by vemurafenib. JAAD
Case Reports 3: 532-533, No. 6, Nov 2017. Available from: URL: http://
doi.org/10.1016/j.jdcr.2017.06.027 - France
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved